ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best penny stocks to buy for 2026. On December 16, ImmunityBio, Inc.
Approval of ANKTIVA was granted for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with ...
Man patients with MIBC are ineligible for or refuse SOC cisplatin. SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic ...
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus ...
Armistice Capital acquired more shares of ImmunityBio as EMA recommended ANKTIVA approval and Q3 2025 product revenue surged ...
ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
The regulator’s Office of Prescription Drug Promotion (OPDP) has already sent out two letters alleging “false or misleading” ...
Urothelial tumours represent the 6th most frequent cancer in men and its incidence continues to rise in both sexes. Fortunately, approximately 75% of ...
Pharmaceutical drugs developed by two local companies received approvals in the European Union last month. On Dec. 12, Culver ...
South Wales Argus on MSN
Veteran awaiting urology test says NHS favours addicts over patients
A Newport veteran awaiting urology tests has questioned NHS priorities as the health board explains a ketamine care pathway.
ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback